Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers

Advanced Drug Delivery Reviews

Volumn 64, Issue 6, 2012, Pages 557-570

  Ensign, Laura M ^a,b   Cone, Richard ^a,c   Hanes, Justin ^a,b,c,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Mucoadhesion; Mucus barrier; Mucus penetrating particles; Oral delivery

Indexed keywords

CONTROLLED RELEASE; DRUG ADMINISTRATION; DRUG CARRIER; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TRACT; GI TRACT; GI TRACT MUCUS; MUCOADHESION; MUCUS BARRIER; MUCUS-PENETRATING PARTICLES; ORAL DELIVERY; ORAL DRUG DELIVERY; POLYMERIC NANOPARTICLES; PROTECTIVE BARRIER; THERAPEUTIC LEVELS;

BIOCHEMISTRY; DRUG DELIVERY; NANOPARTICLES; PHYSIOLOGY;

BODY FLUIDS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; DRUG CARRIER; EUDRAGIT; GANTREZ COPOLYMER; GELATIN; LECTIN; MACROGOL; NANOPARTICLE; POLY(METHYL METHACRYLATE); POLYACRYLIC ACID; POLYCAPROLACTONE; POLYCARBOPHIL; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POLYSEBACIC ACID; POLYSTYRENE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WHEAT GERM AGGLUTININ;

CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG INTESTINE LEVEL; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TRACT; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MUCOADHESION; MUCUS SECRETION; NANOENGINEERING; NONHUMAN; ORAL DRUG ADMINISTRATION; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; STOMACH PH;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; GASTRIC MUCOSA; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL MUCOSA; NANOPARTICLES; POLYMERS; SOLUBILITY;

EID: 84859719708     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.12.009     Document Type: Review

References (128)

1. Schenk M., Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract. Res. Cl Ga 2008, 22:391-409.
2. Frey A., Giannasca K.T., Weltzin R., Giannasca P.J., Reggio H., Lencer W.I., Neutra M.R. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med. 1996, 184:1045-1059.
3. Plapied L., Duhem N., des Rieux A., Preat V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface 2011, 16:228-237.
4. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
5. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
6. Suk J.S., Lai S.K., Boylan N.J., Dawson M.R., Boyle M.P., Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine-UK 2011, 6:365-375.
7. Suk J.S., Lai S.K., Wang Y.Y., Ensign L.M., Zeitlin P.L., Boyle M.P., Hanes J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30:2591-2597.
8. Tang B.C., Dawson M., Lai S.K., Wang Y.Y., Suk J.S., Yang M., Zeitlin P., Boyle M.P., Fu J., Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad Sci. U. S. A. 2009, 106:19268-19273.
9. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew. Chem. Int. Ed. 2008, 47:9726-9729.
10. Yang M., Lai S.K., Wang Y.Y., Zhong W.X., Happe C., Zhang M., Fu J., Hanes J. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. 2011, 50:2597-2600.
11. Corfield A.P., Carroll D., Myerscough N., Probert C.S.J. Mucins in the gastrointestinal tract in health and disease. Front. Biosci. 2001, 6:D1321-D1357.
12. Carlstedt I., Sheehan J.K. Structure and macromolecular properties of mucus glycoproteins. Monogr. Allergy 1988, 24:16-24.
13. Cone R. Mucus. Handbook of Mucosal Immunology 2005, 49-72. Academic Press, London. L. Mestecky, Strober, Bienenstock, McGhee (Eds.).
14. Bansil R., Turner B.S. Mucin structure, aggregation, physiological functions and biomedical applications. Curr. Opin. Colloid Interface 2006, 11:164-170.
15. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4:45-60.
16. Macadam A. The effect of gastrointestinal mucus on drug absorption. Adv. Drug Deliv. Rev. 1993, 11:201-220.
17. Lai S.K., Wang Y.Y., Wirtz D., Hanes J. Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 2009, 61:86-100.
18. Atuma C., Strugala V., Allen A., Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver 2001, 280:G922-G929.
19. Sandzen B., Blom H., Dahlgren S. Gastric mucus gel layer thickness measured by direct light-microscopy - an experimental-study in the rat. Scand. J. Gastroenterol. 1988, 23:1160-1164.
20. Copeman M., Matuz J., Leonard A.J., Pearson J.P., Dettmar P.W., Allen A. The gastroduodenal mucus barrier and its role in protection against luminal pepsins - the effect of 16,16-dimethyl prostaglandin-E(2), carbopol-polyacrylate, sucralfate and bismuth subsalicylate. J. Gastroenterol. Hepatol 1994, 9:S55-S59.
21. Kerss S., Allen A., Garner A. A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric-mucosa - influence of feeding, prostaglandin, n-acetylcysteine and other agents. Clin. Sci. 1982, 63:187-195.
22. Montagne L., Piel C., Lalles J.P. Effect of diet on mucin kinetics and composition: nutrition and health implications. Nutr. Rev. 2004, 62:105-114.
23. Kararli T.T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory-animals. Biopharm. Drug Dispos. 1995, 16:351-380.
24. Bhaskar K.R., Garik P., Turner B.S., Bradley J.D., Bansil R., Stanley H.E., Lamont J.T. Viscous fingering of Hcl through gastric mucin. Nature 1992, 360:458-461.
25. Hastewell J., Williamson I., Mackay M. Cell biology and active-transport processes in the colon. Adv. Drug Deliv. Rev. 1991, 7:119-147.
26. Albanese C.T., Cardona M., Smith S.D., Watkins S., Kurkchubasche A.G., Ulman I., Simmons R.L., Rowe M.I. Role of intestinal mucus in transepithelial passage of bacteria across the intact ileum in-vitro. Surgery 1994, 116:76-82.
27. Sarosiek J., Slomiany A., Takagi A., Slomiany B.L. Hydrogen-ion diffusion in dog gastric mucus glycoprotein - effect of associated lipids and covalently bound fatty-acids. Biochem. Biophys. Res. Commun. 1984, 118:523-531.
28. Witas H., Sarosiek J., Aono M., Murty V.L.N., Slomiany A., Slomiany B.L. Lipids associated with rat small-intestinal mucus glycoprotein. Carbohydr. Res. 1983, 120:67-76.
29. Gwozdzinski K., Slomiany A., Nishikawa H., Okazaki K., Slomiany B.L. Gastric mucin hydrophobicity - effects of associated and covalently bound lipids, proteolysis, and reduction. Biochem. Int. 1988, 17:907-917.
30. Lichtenberger L.M. The hydrophobic barrier properties of gastrointestinal mucus. Annu. Rev. Physiol. 1995, 57:565-583.
31. Murty V.L.N., Sarosiek J., Slomiany A., Slomiany B.L. Effect of lipids and proteins on the viscosity of gastric mucus glycoprotein. Biochem. Biophys. Res. Commun. 1984, 121:521-529.
32. Khanvilkar K., Donovan M.D., Flanagan D.R. Drug transfer through mucus. Adv. Drug Deliv. Rev. 2001, 48:173-193.
33. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl Acad. Sci. U. S. A. 2007, 104:1482-1487.
34. Shirazi T., Longman R.J., Corfield A.P., Probert C.S.J. Mucins and inflammatory bowel disease. Postgrad. Med. J. 2000, 76:473-478.
35. McGuckin M.A., Linden S.K., Sutton P., Florin T.H. Mucin dynamics and enteric pathogens. Nat. Rev. Microbiol. 2011, 9:265-278.
36. Galindo-Rodriguez S.A., Allemann E., Fessi H., Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 2005, 22:419-464.
37. Kreuter J., Muller U., Munz K. Quantitative and microautoradiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles. Int. J. Pharm. 1989, 55:39-45.
38. Florey H.W. Secretion and function of intestinal mucus. Gastroenterology 1962, 43:326-329.
39. Gruber P., Longer M.A., Robinson J.R. Some biological issues in oral, controlled drug delivery. Adv. Drug Deliv. Rev. 1987, 1:1-18.
40. Tirosh B., Rubinstein A. Migration of adhesive and nonadhesive particles in the rat intestine under altered mucus secretion conditions. J. Pharm. Sci. 1998, 87:453-456.
41. Woodley J. Bioadhesion - new possibilities for drug administration?. Clin. Pharmacokinet. 2001, 40:77-84.
42. des Rieux A., Fievez V., Garinot M., Schneider Y.-J., Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 2006, 116:1-27.
43. Chickering D.E., Jacob J.S., Desai T.A., Harrison M., Harris W.P., Morrell C.N., Chaturvedi P., Mathiowitz E. Bioadhesive microspheres. 3. An in vivo transit and bioavailability study of drug-loaded alginate and poly(fumaric-co-sebacic anhydride) microspheres. J. Control. Release 1997, 48:35-46.
44. Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., Santos C.A., Vijayaraghavan K., Montgomery S., Bassett M., Morrell C. Biologically erodable microsphere as potential oral drug delivery system. Nature 1997, 386:410-414.
45. Lowe P.J., Temple C.S. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules - protection against proteases and effect on intestinal-absorption in rats. J. Pharm. Pharmacol. 1994, 46:547-552.
46. Damge C., Vranckx H., Balschmidt P., Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 1997, 86:1403-1409.
47. Tobio M., Sanchez A., Vila A., Soriano I., Evora C., Vila-Jato J.L., Alonso M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid Surf. B 2000, 18:315-323.
48. A.d. Rieux, E.G.E. Ragnarsson, E. Gullberg, V. Préat, Y.-J. Schneider, P. Artursson, Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium, European Journal of Pharmaceutical Sciences, 25 455-465.
49. Eldridge J.H., Hammond C.J., Meulbroek J.A., Staas J.K., Gilley R.M., Tice T.R. Controlled vaccine release in the gut-associated lymphoid-tissues. 1. Orally-administered biodegradable microspheres target the Peyer's patches. J. Control. Release 1990, 11:205-214.
50. Behrens I., Pena A.I.V., Alonso M.J., Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 2002, 19:1185-1193.
51. Bravo-Osuna I., Vauthier C., Farabollini A., Palmieri G.F., Ponchel G. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 2007, 28:2233-2243.
52. Park J.H., Saravanakumar G., Kim K., Kwon I.C. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 2010, 62:28-41.
53. Roy K., Mao H.Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 1999, 5:387-391.
54. Takeuchi H., Thongborisute J., Matsui Y., Sugihara H., Yamamoto H., Kawashima Y. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv. Drug Deliv. Rev. 2005, 57:1583-1594.
55. Vila A., Sanchez A., Tobio M., Calvo P., Alonso M.J. Design of biodegradable particles for protein delivery. J. Control. Release 2002, 78:15-24.
56. Kawashima Y., Yamamoto H., Takeuchi H., Kuno Y. Mucoadhesive dl-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol. 2000, 5:77-85.
57. Schipper N.G.M., Varum K.M., Stenberg P., Ocklind G., Lennernas H., Artursson P. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. Eur. J. Pharm. Sci. 1999, 8:335-343.
58. Jani P., Halbert G.W., Langridge J., Florence A.T. The uptake and translocation of latex nanospheres and microspheres after oral-administration to rats. J. Pharm. Pharmacol. 1989, 41:809-812.
59. Roger E., Lagarce F., Garcion E., Benoit J.P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine-UK 2010, 5:287-306.
60. Norris D.A., Puri N., Sinko P.J. The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 1998, 34:135-154.
61. Hussain N., Jaitley V., Florence A.T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 2001, 50:107-142.
62. Eyles J., Alpar H.O., Field W.N., Lewis D.A., Keswick M. The transfer of polystyrene microspheres from the gastrointestinal-tract to the circulation after oral-administration in the rat. J. Pharm. Pharmacol. 1995, 47:561-565.
63. Gabor F., Bogner E., Weissenboeck A., Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv. Drug Deliv. Rev. 2004, 56:459-480.
64. Bies C., Lehr C.M., Woodley J.F. Lectin-mediated drug targeting: history and applications. Adv. Drug Deliv. Rev. 2004, 56:425-435.
65. Harokopakis E., Hajishengallis G., Michalek S.M. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect. Immun. 1998, 66:4299-4304.
66. Dawson G.F., Halbert G.W. The in vitro cell association of invasin coated polylactide-co-glycolide nanoparticles. Pharm. Res. 2000, 17:1420-1425.
67. Russell-Jones G.J., Arthur L., Walker H. Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. Int. J. Pharm. 1999, 179:247-255.
68. Clark M.A., Hirst B.H., Jepson M.A. Lectin-mediated mucosal delivery of drugs and microparticles. Adv. Drug Deliv. Rev. 2000, 43:207-223.
69. Irache J.M., Durrer C., Duchene D., Ponchel G. Preparation and characterization of lectin-latex conjugates for specific bioadhesion. Biomaterials 1994, 15:899-904.
70. Lehr C.-M., Bouwstra J.A., Kok W., Noach A.B.J., de Boer A.G., Junginger H.E. Bioadhesion by means of specific binding of tomato lectin. Pharm. Res. 1992, 9:547-553.
71. Hussain N., Jani P.U., Florence A.T. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res. 1997, 14:613-618.
72. Owen R.L., Bhalla D.K. Cytochemical analysis of alkaline-phosphatase and esterase-activities and of lectin-binding and anionic sites in rat and mouse Peyer's patch M-cells. Am. J. Anat. 1983, 168:199-212.
73. Nagata Y., Burger M.M. Wheat germ agglutinin. J. Biol. Chem. 1974, 249:3116-3122.
74. Yin Y.S., Chen D.W., Qiao M.X., Lu Z., Hu H.Y. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J. Control. Release 2006, 116:337-345.
75. Yin Y.S., Chen D.W., Qiao M.X., Wei X.Y., Hu H.Y. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control. Release 2007, 123:27-38.
76. Hussain N., Florence A.T. Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles. Pharm. Res. 1998, 15:153-156.
77. Salman H.H., Gamazo C., Campanero M.A., Irache J.M. Salmonella-like bioadhesive nanoparticles. J. Control. Release 2005, 106:1-13.
78. Bhavsar M.D., Amiji M.M. Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin. Drug Deliv. 2007, 4:197-213.
79. Bhavsar M.D., Amiji M.M. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Release 2007, 119:339-348.
80. Bhavsar M.D., Amiji M.M. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008, 15:1200-1209.
81. LihBrody L., Powell S.R., Collier K.P., Reddy G.M., Cerchia R., Kahn E., Weissman G.S., Katz S., Floyd R.A., McKinley M.J., Fisher S.E., Mullin G.E. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig. Dis. Sci. 1996, 41:2078-2086.
82. Peng Y.C., Hsu C.L., Tung C.F., Chou W.K., Huang L.R., Hung D.Z., Hu W.H., Yang D.Y. Chemiluminescence assay of mucosal reactive oxygen species in gastric cancer, ulcer and antral mucosa. Hepatogastroenterology 2008, 55:770-773.
83. Kountouras J., Chatzopoulos D., Zavos C. Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology 2001, 48:743-751.
84. Wilson D.S., Dalmasso G., Wang L.X., Sitaraman S.V., Merlin D., Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 2010, 9:923-928.
85. Lamprecht A., Schafer U., Lehr C.M. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 2001, 18:788-793.
86. Evans D.F., Pye G., Bramley R., Clark A.G., Dyson T.J., Hardcastle J.D. Measurement of gastrointestinal pH profiles in normal ambulant human-subjects. Gut 1988, 29:1035-1041.
87. Gao W.W., Chan J.M., Farokhzad O.C. pH-responsive nanoparticles for drug delivery. Mol. Pharm. 2010, 7:1913-1920.
88. Dai S., Tam K.C., Jenkins R.D. Aggregation behavior of methacrylic acid/ethyl acrylate copolymer in dilute solutions. Eur. Polym. J. 2000, 36:2671-2677.
89. Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 2008, 126:187-204.
90. Bajpai A.K., Shukla S.K., Bhanu S., Kankane S. Responsive polymers in controlled drug delivery. Prog. Polym. Sci. 2008, 33:1088-1118.
91. Lin Y.H., Sonaje K., Lin K.M., Juang J.H., Mi F.L., Yang H.W., Sung H.W. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J. Control. Release 2008, 132:141-149.
92. Sonaje K., Lin K.J., Wey S.P., Lin C.K., Yeh T.H., Nguyen H.N., Hsua C.W., Yen T.C., Juang J.H., Sung H.W. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010, 31:6849-6858.
93. McConnell E.L., Short M.D., Basit A.W. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J. Control. Release 2008, 130:154-160.
94. Ibekwe V.C., Fadda H.M., McConnell E.L., Khela M.K., Evans D.F., Basit A.W. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm. Res. 2008, 25:1828-1835.
95. Fricker G., Kromp T., Wendel A., Blume A., Zirkel J., Rebmann H., Setzer C., Quinkert R.O., Martin F., Muller-Goymann C. Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res. 2010, 27:1469-1486.
96. Pouton C.W., Porter C.J.H. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv. Drug Deliv. Rev. 2008, 60:625-637.
97. O'Neill M.J., Bourre L., Melgar S., O'Driscoll C.M. Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. Drug Discov. Today 2011, 16:203-218.
98. He C.X., He Z.G., Gao J.Q. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. Expert Opin. Drug Deliv. 2010, 7:445-460.
99. Hida K., Lai S.K., Suk J.S., Won S.Y., Boyle M.P., Hanes J. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PLoS One 2011, 6:e19919.
100. Khan J., Iiboshi Y., Cui L., Wasa M., Okada A. Role of intestinal mucus on the uptake of latex beads by Peyer's patches and on their transport to mesenteric lymph nodes in rats. JPEN J. Parenter. Enteral Nutr. 1999, 23:19-23.
101. Gupta P.K., Leung S.-H.S., Robinson J.R. Bioadhesives/Mucoadhesives in Drug Delivery to the Gastrointestinal Tract. Bioadhesive Drug Delivery Systems 1990, CRC Press Inc., Boca Raton. V. Lenaerts, R. Gurny (Eds.).
102. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 2001, 81:1930-1937.
103. Paerregaard A., Espersen F., Jensen O.M., Skurnik M. Interactions between Yersinia enterocolitica and rabbit ileal mucus - growth, adhesion, penetration, and subsequent changes in surface hydrophobicity and ability to adhere to ileal brush-border membrane-vesicles. Infect. Immun. 1991, 59:253-260.
104. Larhed A.W., Artursson P., Bjork E. The influence of intestinal mucus components on the diffusion of drugs. Pharm. Res. 1998, 15:66-71.
105. Larhed A.W., Artursson P., Grasjo J., Bjork E. Diffusion of drugs in native and purified gastrointestinal mucus. J. Pharm. Sci. 1997, 86:660-665.
106. Primard C., Rochereau N., Luciani E., Genin C., Delair T., Paul S., Verrier B. Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. Biomaterials 2010, 31:6060-6068.
107. Szentkuti L. Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon. J. Control. Release 1997, 46:233-242.
108. Lieleg O., Vladescu I., Ribbeck K. Characterization of particle translocation through mucin hydrogels. Biophys. J. 2010, 98:1782-1789.
109. Crater J.S., Carrier R.L. Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol. Biosci. 2010, 10:1473-1483.
110. Lai S.K., Hida K., Shukair S., Wang Y.Y., Figueiredo A., Cone R., Hope T.J., Hanes J. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J. Virol. 2009, 83:11196-11200.
111. Lai S.K., Wang Y.Y., Cone R., Wirtz D., Hanes J. Altering mucus rheology to "solidify"' human mucus at the nanoscale. PLoS One 2009, 4:e4294.
112. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad Sci. U. S. A. 2010, 107:598-603.
113. Owen D.A., Reid P.E. Histochemical alterations of mucin in normal colon, inflammatory bowel-disease and colonic adenocarcinoma. Histochem. J. 1995, 27:882-889.
114. Ota H., Nakayama J., Momose M., Hayama M., Akamatsu T., Katsuyama T., Graham D.Y., Genta R.M. Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Virchows Arch. 1998, 433:419-426.
115. Mccormick D.A., Horton L.W.L., Mee A.S. Mucin depletion in inflammatory bowel-disease. J. Clin. Pathol. 1990, 43:143-146.
116. Pullan R.D., Thomas G.A.O., Rhodes M., Newcombe R.G., Williams G.T., Allen A., Rhodes J. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994, 35:353-359.
117. Longman R.J., Poulsom R., Corfield A.P., Warren B.F., Wright N.A., Thomas M.G. Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis. J. Histochem. Cytochem. 2006, 54:1335-1348.
118. Ehehalt R., Wagenblast J., Erben G., Lehmann W.D., Hinz U., Merle U., Stremmel W. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients, a quantitative approach by nanoelectrospray-tandem mass spectrometry. Scand. J. Gastroenterol. 2004, 39:737-742.
119. Braun A., Treede I., Gotthardt D., Tietje A., Zahn A., Ruhwald R., Schoenfeld U., Welsch T., Kienle P., Erben G., Lehmann W.D., Fuellekrug J., Stremmel W., Ehehalt R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm. Bowel Dis. 2009, 15:1705-1720.
120. Schneider H., Braun A., Fullekrug J., Stremmel W., Ehehalt R. Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation. Int. J. Mol. Sci. 2010, 11:4149-4164.
121. Stremmel W., Braun A., Hanemann A., Ehehalt R., Autschbach F., Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J. Clin. Gastroenterol. 2010, 44:E101-E107.
122. Jain A., Jain S.K. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur. J. Pharm. Sci. 2008, 35:404-416.
123. Kanthamneni N., Chaudhary A., Wang J., Prabhu S. Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. Int. J. Oncol. 2010, 37:177-185.
124. Feng S.S. New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?. Nanomedicine-UK 2006, 1:297-309.
125. Wang X., Shah A.A., Campbell R.B., Wan K.T. Glycoprotein mucin molecular brush on cancer cell surface acting as mechanical barrier against drug delivery. Appl. Phys. Lett. 2010, 97:26370.
126. Kufe D.W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 2009, 9:874-885.
127. Lamprecht A., Ubrich N., Yamamoto H., Schafer U., Takeuchi H., Maincent P., Kawashima Y., Lehr C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 2001, 299:775-781.
128. Jha B., Cueto-Felgueroso L., Juanes R. Fluid mixing from viscous fingering. Phys. Rev. Lett. 2011, 106:194502.